Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business Strategy

Set Alert for Business Strategy

The 10 US Biosimilar Launches That Could Drive Big Savings By 2027

Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.

Biosimilars US States

AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis

Already approved in Crohn’s disease, Skyrizi now has positive Phase III results in ulcerative colitis with more data expected this year in UC as the field grows more crowded with anti-IL-23 options.

Clinical Trials Gastrointestinal

Cidara’s Novel Antifungal Approved For Antimicrobial-Resistant C. Auris Infections

Cidara’s US commercial partner Melinta will launch the novel echinocandin this summer, announcing pricing shortly before rollout. Limited indication follows recommendation of FDA advisory panel.

Approvals Business Strategies

Generation Bio’s LNP DNA-Delivery Platform Gets Big Boost From Moderna

The company aims to deliver DNA via lipid nanoparticles as well as delivering LNPs systemically to tissues beyond the liver and spleen, which the CEO called a “frontier” in an interview.

Deals Platform Technologies

Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD

Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.

Respiratory Inflammation

PureTech Cashes In On Promise Of Karuna Schizophrenia Drug

Karuna’s KarXT could be the first new mechanism for treating schizophrenia approved in more than 50 years and founder PureTech is tapping into that promise by linking up with Royalty Pharma and boosting its cashpile.

Deals Neurology

Ease The Pain – Making Payment Models, Tech, Integration Work For Patients

Multiple payment models, including differential pricing for pooled purchases, and technology-based healthcare platforms are some of the ways to build a patient-centric ecosystem said officials from Roche, VCs and non-government bodies at a recent conference

Commercial Business Strategies

Finance Watch: Biotech Valuations Seesaw On Bank Failure, Pharma M&A

Public Company Edition: The closure of Silicon Valley Bank sank biotech stocks in the first full week of March, but valuations rose the next week when two big acquisitions were announced. Also, J&J’s consumer health spinout sold $7.75bn in notes ahead of its future IPO and Karuna grossed $400m in a follow-on offering.

Financing Business Strategies

89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class

89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.

Clinical Trials Business Strategies

Biohaven Makes Bet On Brain-Penetrant TYK2/JAK1 Inhibitor For Neurological Diseases

The company, which has struggled in the clinic following a deal where Pfizer bought its migraine portfolio, is licensing the dual inhibitor drug from a Chinese firm for up to $970m.

Deals Business Strategies

AbbVie Data Show Skyrizi Tops IL-17 Competitors In Skin Clearance

Skyrizi showed better skin-clearance results than Cosentyx or Taltz in a 52-week study of patients who had suboptimal results on the latter two drugs.

Clinical Trials Business Strategies

Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate

Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.

Deal Watch Business Strategies
See All
UsernamePublicRestriction

Register